Search alternatives:
significant linear » significant clinical (Expand Search), significant level (Expand Search), significant gender (Expand Search)
linear increase » year increase (Expand Search)
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), teer decrease (Expand Search), we decrease (Expand Search)
Showing 121 - 140 results of 24,989 for search '(( significant linear increase ) OR ( significantly ((lower decrease) OR (larger decrease)) ))', query time: 0.44s Refine Results
  1. 121
    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is).

    The results of KEGG enrichment analysis (Annotation: Circles represent each pathway, and the redder the color, the larger the circle, and the more important it is). by Lin Zhou (141050)

    Published 2023
    Save to List
    Saved in:
  2. 122
    Correlogram indicating a prominent, moderately significant lead between flowering and rainfall at position 1.

    Correlogram indicating a prominent, moderately significant lead between flowering and rainfall at position 1. by Alan Barrett (631256)

    Published 2021
    Save to List
    Saved in:
  3. 123
    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in the N-deficient treatment.

    Traits at cellular, leaf, and whole-plant scales which were significantly different [increased (↑) or decreased (↓)] or non-significant between tolerant and sensitive cultivars in... by Ranjeeta Adhikari (9905958)

    Published 2023
    Save to List
    Saved in:
  4. 124
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  5. 125
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 126
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 127
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 128
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 129
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 130
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 131
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 132
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 133
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 134
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 135
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 136
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 137
    S1 Data -

    S1 Data - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 138
    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups.

    Trend of TI values with age: The TI values decreased significantly with the increase of age, * p<0.01 vs other groups. by Yunmeng Da (707943)

    Published 2024
    Save to List
    Saved in:
  19. 139
    Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoids during the observed time period.

    Join-point regression analysis of the statistically significant linear increase in use of anxiolytics, psychostimulants and noot ropic drugs, sedatives and hypnotics, gabapentinoids during the observed time period. by Jelena Filimonovic (22305307)

    Published 2025
    Save to List
    Saved in:
  20. 140
    Decreased childhood asthma hospitalizations linked to hotter, drier climate with lower wind speed in drylands

    Decreased childhood asthma hospitalizations linked to hotter, drier climate with lower wind speed in drylands by Klézio Silva Monte (20579829)

    Published 2025
    Save to List
    Saved in:

Search Tools: